In five clinical trials involving 317 patients with SVT, Rapiblyk reduced heart rate in 40% to 90% of them within about 10 minutes, compared to a placebo that reduced heart rate in 0%-11% of them.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback